《新股消息》泉源堂大药房递上市申请 传筹3亿美元
内地智慧零售药房泉源堂大药房日前已向联交所提交主板上市申请,联席保荐人为花旗及海通国际。外电引述消息指,泉源堂目标集资约2亿至3亿美元。
初步招股文件显示,泉源堂於中国经营全渠道零售药房业务,目前已设立369间线下零售药房及38间线上药房,截至2020年底止与逾1,000家制药企业合作,药房SKU数量超过3万种。去年度公司录得亏损1.55亿元人民币,较2019年的1.66亿元人民币收窄。
中生制药(01177.HK)为其股东,透过附属QYT及裕势持有公司上市前合共近33.4%股份。另外,美国投资公司海纳国际、上海方正韩投股权投资、重庆国资委旗下和亚投资及景诚(成都)股权投资基金等,均为上市前投资者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.